| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1051669271 |
| P356 | DOI | 10.1038/EMM.2016.111 |
| P3181 | OpenCitations bibliographic resource ID | 2978712 |
| P932 | PMC publication ID | 5099421 |
| P698 | PubMed publication ID | 27741224 |
| P50 | author | Magdy M. Mahfouz | Q40790243 |
| P2093 | author name string | Ayman Eid | |
| P2860 | cites work | CRISPR Provides Acquired Resistance Against Viruses in Prokaryotes | Q21508827 |
| CRISPR germline engineering--the community speaks | Q41238392 | ||
| DNA-guided DNA interference by a prokaryotic Argonaute | Q41401449 | ||
| Targeted genome editing in human repopulating haematopoietic stem cells | Q41822307 | ||
| Unbiased detection of off-target cleavage by CRISPR-Cas9 and TALENs using integrase-defective lentiviral vectors. | Q42174678 | ||
| Recognition of methylated DNA by TAL effectors | Q42532357 | ||
| Rapid and highly efficient construction of TALE-based transcriptional regulators and nucleases for genome modification | Q43240978 | ||
| RNA-guided transcriptional regulation in planta via synthetic dCas9-based transcription factors. | Q45909715 | ||
| Human Genome Editing and Ethical Considerations. | Q47397544 | ||
| Impact of next generation sequencing: the 2009 Human Genome Variation Society Scientific Meeting | Q51141178 | ||
| Off-target assessment of CRISPR-Cas9 guiding RNAs in human iPS and mouse ES cells | Q52423222 | ||
| The return of germline gene therapy | Q53436485 | ||
| A comprehensive species to strain taxonomic framework for xanthomonas. | Q54511272 | ||
| Knockout rats generated by embryo microinjection of TALENs. | Q55054726 | ||
| TALE nucleases and next generation GM crops | Q64386673 | ||
| Impact of human genome sequencing for in silico target discovery | Q73637675 | ||
| Initial impact of the sequencing of the human genome | Q22122172 | ||
| Crystal structure of a five-finger GLI-DNA complex: new perspectives on zinc fingers | Q24313462 | ||
| Zinc finger nucleases: custom-designed molecular scissors for genome engineering of plant and mammalian cells | Q24535831 | ||
| Hybrid restriction enzymes: zinc finger fusions to Fok I cleavage domain | Q24567623 | ||
| RNA-guided human genome engineering via Cas9 | Q24598394 | ||
| Targeting DNA double-strand breaks with TAL effector nucleases | Q24605087 | ||
| Transformation of yeast | Q24605273 | ||
| Multiplex genome engineering using CRISPR/Cas systems | Q24609428 | ||
| De novo-engineered transcription activator-like effector (TALE) hybrid nuclease with novel DNA binding specificity creates double-strand breaks | Q24624851 | ||
| Fok I dimerization is required for DNA cleavage | Q24657843 | ||
| Cpf1 is a single RNA-guided endonuclease of a class 2 CRISPR-Cas system | Q24669821 | ||
| A Programmable Dual-RNA-Guided DNA Endonuclease in Adaptive Bacterial Immunity | Q24669850 | ||
| How specific is CRISPR/Cas9 really? | Q26777801 | ||
| Making designer mutants in model organisms | Q27010108 | ||
| Measuring and Reducing Off-Target Activities of Programmable Nucleases Including CRISPR-Cas9 | Q27011906 | ||
| Structural Basis for Sequence-Specific Recognition of DNA by TAL Effectors | Q27676611 | ||
| The crystal structure of Cpf1 in complex with CRISPR RNA | Q27704663 | ||
| The DNA Damage Response: Making It Safe to Play with Knives | Q27861055 | ||
| Therapeutic genome editing: prospects and challenges | Q28087380 | ||
| Enhancing Gene Targeting with Designed Zinc Finger Nucleases | Q28202461 | ||
| Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV | Q28235281 | ||
| In vivo genome editing restores haemostasis in a mouse model of haemophilia | Q28241725 | ||
| A simple cipher governs DNA recognition by TAL effectors | Q28265506 | ||
| Breaking the code of DNA binding specificity of TAL-type III effectors | Q28265515 | ||
| Mitotic homologous recombination maintains genomic stability and suppresses tumorigenesis | Q28274000 | ||
| Zinc-finger nucleases: the next generation emerges | Q28283445 | ||
| Genome editing with engineered zinc finger nucleases | Q28290795 | ||
| A TALE nuclease architecture for efficient genome editing | Q28301656 | ||
| Pathways of DNA double-strand break repair during the mammalian cell cycle | Q28608969 | ||
| Fusion of catalytically inactive Cas9 to FokI nuclease improves the specificity of genome modification | Q29029259 | ||
| UK scientists gain licence to edit genes in human embryos | Q29039750 | ||
| Disruption of the proto-oncogene int-2 in mouse embryo-derived stem cells: a general strategy for targeting mutations to non-selectable genes | Q29547355 | ||
| Replacement of chromosome segments with altered DNA sequences constructed in vitro | Q29614231 | ||
| Cas9–crRNA ribonucleoprotein complex mediates specific DNA cleavage for adaptive immunity in bacteria | Q29614420 | ||
| Playing the end game: DNA double-strand break repair pathway choice | Q29614837 | ||
| Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity | Q29615792 | ||
| DNA targeting specificity of RNA-guided Cas9 nucleases | Q29615793 | ||
| Improving CRISPR-Cas nuclease specificity using truncated guide RNAs | Q29616043 | ||
| High-frequency off-target mutagenesis induced by CRISPR-Cas nucleases in human cells | Q29616045 | ||
| Clustered regularly interspaced short palindrome repeats (CRISPRs) have spacers of extrachromosomal origin | Q29617073 | ||
| CRISPR interference: RNA-directed adaptive immunity in bacteria and archaea | Q29617488 | ||
| A bacterial effector acts as a plant transcription factor and induces a cell size regulator | Q30319733 | ||
| Plant pathogen recognition mediated by promoter activation of the pepper Bs3 resistance gene | Q30319734 | ||
| Loss-of-function mutations in APOC3, triglycerides, and coronary disease | Q30408720 | ||
| An updated evolutionary classification of CRISPR-Cas systems | Q33660852 | ||
| CRISPR/Cas9 systems have off-target activity with insertions or deletions between target DNA and guide RNA sequences | Q33791286 | ||
| Dimeric CRISPR RNA-guided FokI nucleases for highly specific genome editing | Q33875102 | ||
| Stimulation of homologous recombination through targeted cleavage by chimeric nucleases | Q33927812 | ||
| RNA-directed gene editing specifically eradicates latent and prevents new HIV-1 infection. | Q34025414 | ||
| Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype. | Q34040385 | ||
| Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex | Q34042665 | ||
| CRISPR/Cas9-mediated viral interference in plants | Q34045362 | ||
| Rationally engineered Cas9 nucleases with improved specificity | Q34045530 | ||
| Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo | Q34124290 | ||
| Characterization and DNA-binding specificities of Ralstonia TAL-like effectors | Q34321624 | ||
| Foamy virus vector integration sites in normal human cells | Q34334976 | ||
| Lentiviral hematopoietic stem cell gene therapy in patients with Wiskott-Aldrich syndrome. | Q34356904 | ||
| Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. | Q34385127 | ||
| Genome-Scale CRISPR-Mediated Control of Gene Repression and Activation | Q34443093 | ||
| Correction of a genetic disease by CRISPR-Cas9-mediated gene editing in mouse spermatogonial stem cells | Q34452056 | ||
| GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases | Q34454104 | ||
| The CRISPR/Cas9 System Facilitates Clearance of the Intrahepatic HBV Templates In Vivo | Q34459390 | ||
| Small molecule-triggered Cas9 protein with improved genome-editing specificity | Q34470608 | ||
| Applications of the CRISPR-Cas9 system in cancer biology | Q34479139 | ||
| Functional Correction of Large Factor VIII Gene Chromosomal Inversions in Hemophilia A Patient-Derived iPSCs Using CRISPR-Cas9. | Q34486935 | ||
| CRISPR/Cas9 somatic multiplex-mutagenesis for high-throughput functional cancer genomics in mice | Q34499647 | ||
| High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects. | Q34507554 | ||
| The CRISPR-associated DNA-cleaving enzyme Cpf1 also processes precursor CRISPR RNA. | Q34522844 | ||
| Genome-wide detection of DNA double-stranded breaks induced by engineered nucleases. | Q35060760 | ||
| Efficient fdCas9 Synthetic Endonuclease with Improved Specificity for Precise Genome Engineering | Q35725869 | ||
| Genome-wide specificity of DNA binding, gene regulation, and chromatin remodeling by TALE- and CRISPR/Cas9-based transcriptional activators | Q35876055 | ||
| Crystal Structure of Cpf1 in Complex with Guide RNA and Target DNA | Q35999041 | ||
| Homologous recombination and its regulation | Q36106937 | ||
| Structure and specificity of the RNA-guided endonuclease Cas9 during DNA interrogation, target binding and cleavage | Q36160691 | ||
| A TALEN genome-editing system for generating human stem cell-based disease models | Q36604889 | ||
| Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients | Q36812729 | ||
| In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy. | Q36943717 | ||
| Inactivation of hepatitis B virus replication in cultured cells and in vivo with engineered transcription activator-like effector nucleases. | Q37254885 | ||
| Analysis of off-target effects of CRISPR/Cas-derived RNA-guided endonucleases and nickases. | Q37420333 | ||
| RNA-directed DNA methylation: mechanisms and functions | Q37737507 | ||
| Engineering adeno-associated viruses for clinical gene therapy | Q38212776 | ||
| Genome engineering via TALENs and CRISPR/Cas9 systems: challenges and perspectives | Q38253811 | ||
| Recent developments and clinical studies utilizing engineered zinc finger nuclease technology. | Q38531847 | ||
| CRISPR-Cas: New Tools for Genetic Manipulations from Bacterial Immunity Systems | Q38553835 | ||
| CRISPR/Cas9 system as an innovative genetic engineering tool: Enhancements in sequence specificity and delivery methods | Q38598808 | ||
| CRISPR/Cas9: molecular tool for gene therapy to target genome and epigenome in the treatment of lung cancer | Q38614582 | ||
| Pharmacological inhibition of DNA-PK stimulates Cas9-mediated genome editing | Q38840857 | ||
| Functional interpretation of non-coding sequence variation: concepts and challenges | Q38843497 | ||
| Activities and specificities of homodimeric TALENs in Saccharomyces cerevisiae. | Q38877482 | ||
| Generation of gene-modified cynomolgus monkey via Cas9/RNA-mediated gene targeting in one-cell embryos. | Q39028341 | ||
| Targeted transcriptional repression using a chimeric TALE-SRDX repressor protein. | Q40435603 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International | Q24082749 |
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | regulation of gene expression | Q411391 |
| CRISPR | Q412563 | ||
| Cas9 | Q16965677 | ||
| CRISPR-Cas method | Q17310682 | ||
| gene editing | Q65363531 | ||
| biomedical investigative technique | Q66648976 | ||
| CRISPR-Cas systems | Q71149179 | ||
| P304 | page(s) | e265 | |
| P577 | publication date | 2016-10-14 | |
| P13046 | publication type of scholarly work | review article | Q7318358 |
| P1433 | published in | Experimental and Molecular Medicine | Q15758292 |
| P1476 | title | Genome editing: the road of CRISPR/Cas9 from bench to clinic | |
| P478 | volume | 48 |
| Q41840547 | A CRISPR/Cas9-based method and primer design tool for seamless genome editing in fission yeast. |
| Q55172646 | CRISPR base editors: genome editing without double-stranded breaks. |
| Q90483284 | CRISPR/Cas Systems in Genome Editing: Methodologies and Tools for sgRNA Design, Off-Target Evaluation, and Strategies to Mitigate Off-Target Effects |
| Q89873570 | CRISPR/Cas9-mediated genome editing: From basic research to translational medicine |
| Q55263970 | CRISPR/Cas9: the Jedi against the dark empire of diseases. |
| Q58710754 | CRISPR/Cas9‑mediated hypoxia inducible factor‑1α knockout enhances the antitumor effect of transarterial embolization in hepatocellular carcinoma |
| Q60919346 | Development of immunocompatible pluripotent stem cells via CRISPR-based human leukocyte antigen engineering |
| Q58694895 | Engineering plant architecture via CRISPR/Cas9-mediated alteration of strigolactone biosynthesis |
| Q55017665 | Epigenetic Targeting of Granulin in Hepatoma Cells by Synthetic CRISPR dCas9 Epi-suppressors. |
| Q64387941 | Gene Editing in Clinical Practice: Where are We? |
| Q50978382 | Genome editing: The efficient tool CRISPR-Cpf1. |
| Q64081310 | Genome-Editing Technologies: Concept, Pros, and Cons of Various Genome-Editing Techniques and Bioethical Concerns for Clinical Application |
| Q94572526 | Process for an efficient lentiviral cell transduction |
| Q41170353 | Recent Advancements in the Regeneration of Auditory Hair Cells and Hearing Restoration |
| Q38769494 | TALENs and CRISPR/Cas9 fuel genetically engineered clinically relevant Xenopus tropicalis tumor models. |
| Q59795578 | The genetic basis of disease |
| Q39290620 | The role of the microbiome in cancer development and therapy |
| Q63246521 | Two decades of embryonic stem cells: a historical overview |
Search more.